Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Novartis
Eastern Cooperative Oncology Group
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
AbbVie
Children's Cancer Group, China
CareDx
Center for International Blood and Marrow Transplant Research
Novartis
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
Orca Biosystems, Inc.
Servier
Children's Oncology Group
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Pennsylvania
University of Miami
Baylor College of Medicine
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Center for International Blood and Marrow Transplant Research
Washington University School of Medicine
City of Hope Medical Center
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Columbia University
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Children's Oncology Group
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Rigshospitalet, Denmark
City of Hope Medical Center
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Bambino Gesù Hospital and Research Institute